We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M Turnover 44%
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+29.13%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$244M
AUM Growth
+$22M
Cap. Flow
+$5.32M
Cap. Flow %
2.18%
Top 10 Hldgs %
43.92%
Holding
93
New
19
Increased
15
Reduced
7
Closed
46
Avg Time Held Equity + Options
0.3 years
Top 10 Avg Time Held Equity + Options
0.1 years
Top 20 Avg Time Held Equity + Options
0.1 years
Avg Time Held Equity only
0.4 years
Top 10 Avg Time Held Equity only
0.1 years
Top 20 Avg Time Held Equity only
0.1 years

Sector Composition

Rank Sector Weight
1 Healthcare 95.9%
2 Miscellaneous 4.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
NUVA
1
DELISTED
NuVasive
NUVA
$12.4M 5.1%
230,000
+55,000
+31% +$2.8M
2014 Q3
5 quarters
AMGN icon
2
Amgen
AMGN
$236B
$12.2M 4.99%
75,000
+25,000
+50% +$3.93M
2015 Q3
1 quarter
WMGI
3
DELISTED
Wright Medical Group
WMGI
$12.1M 4.95%
+500,000
New +$10.8M
2015 Q4
0 quarters
PTLA
4
DELISTED
Portola Pharmaceuticals
PTLA
$11.8M 4.85%
230,000
+205,000
+820% +$9.9M
2014 Q3
5 quarters
SAGE icon
5
DELISTED
Sage Therapeutics
SAGE
$11.7M 4.77%
200,000
+159,200
+390% +$7.89M
2015 Q1
3 quarters
SGEN
6
DELISTED
Seagen
SGEN
$10.1M 4.13%
+225,000
New +$9.37M
2015 Q4
0 quarters
MNK
7
DELISTED
Mallinckrodt
MNK
$10.1M 4.13%
135,000
+15,000
+13% +$1.01M
2015 Q3
1 quarter
PACB icon
8
Pacific Biosciences
PACB
$509M
$9.8M 4.03%
+750,000
New +$6.73M
2015 Q4
0 quarters
ACAD icon
9
Acadia Pharmaceuticals
ACAD
$2.96B
$8.91M 3.65%
+250,000
New +$8.81M
2015 Q4
0 quarters
IART icon
10
Integra LifeSciences
IART
$1.03B
$8.13M 3.33%
240,000
+90,000
+60% +$2.81M
2015 Q3
1 quarter
MRTX
11
DELISTED
Mirati Therapeutics
MRTX
$7.9M 3.23%
+250,000
New +$8.83M
2015 Q4
0 quarters
ZLTQ
12
DELISTED
Zeltiq Aesthetics
ZLTQ
$7.85M 3.21%
275,000
+40,000
+17% +$1.26M
2014 Q3
5 quarters
BLUE icon
13
DELISTED
bluebird bio
BLUE
$7.71M 3.16%
+9,264
New +$9.25M
2015 Q4
0 quarters
BIIB icon
14
Biogen
BIIB
$36.9B
$7.66M 3.14%
+25,000
New +$7.18M
2015 Q4
0 quarters
SPNC
15
DELISTED
Spectranetics
SPNC
$6.55M 2.68%
435,000
+185,000
+74% +$2.44M
2015 Q3
1 quarter
ACHN
16
DELISTED
Achillion Pharmaceuticals
ACHN
$6.47M 2.65%
600,000
+300,000
+100% +$2.73M
2015 Q3
1 quarter
PRTA icon
17
Prothena
PRTA
$422M
$6.13M 2.51%
+90,000
New +$5.43M
2015 Q4
0 quarters
NSTG
18
DELISTED
NanoString Technologies
NSTG
$5.88M 2.41%
400,000
-50,000
-11% -$736K
2014 Q1
7 quarters
NVRO icon
19
DELISTED
Nevro
NVRO
$5.74M 2.35%
+85,000
New +$4.55M
2015 Q4
0 quarters
INCY icon
20
Incyte
INCY
$23.4B
$5.42M 2.22%
50,000
+25,000
+100% +$2.79M
2015 Q3
1 quarter
DBVT icon
21
DBV Technologies
DBVT
$567M
$5.31M 2.18%
+8,000
New +$2.8M
2015 Q4
0 quarters
VTAE
22
DELISTED
Vitae Pharmaceuticals
VTAE
$4.98M 2.04%
275,000
+25,000
+10% +$344K
2015 Q1
3 quarters
ACOR
23
DELISTED
Acorda Therapeutics
ACOR
$4.28M 1.75%
833
– –
2015 Q3
1 quarter
ALNY icon
24
Alnylam Pharmaceuticals
ALNY
$19.3B
$4.24M 1.73%
+45,000
New +$4.17M
2015 Q4
0 quarters
FPRX
25
DELISTED
Five Prime Therapeutics
FPRX
$4.15M 1.7%
100,000
-400,000
-80% -$13.4M
2015 Q1
3 quarters

Similar funds

Ghost Tree Capital's Q4 2015 Portfolio in Review

As of Q4 2015, Ghost Tree Capital held 93 positions worth $244M, up 9.9% from $222M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Ghost Tree Capital's Q4 2015 filing shows 19 new, 15 increased, 7 reduced and 46 closed positions. Its largest new stake was Wright Medical Group: 500,000 shares worth $12.1M. The largest sale was Five Prime Therapeutics, an estimated $13.4M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 85% a quarter earlier, followed by Miscellaneous.

  • Ghost Tree Capital's largest Q4 2015 buy was Wright Medical Group: 500,000 shares worth $12.1M.
  • Ghost Tree Capital added most to Portola Pharmaceuticals in Q4 2015, an estimated $9.9M increase.
  • Ghost Tree Capital's biggest Q4 2015 reduction was Five Prime Therapeutics, cutting an estimated $13.4M.
  • Ghost Tree Capital fully exited Allergan plc in Q4 2015, selling an estimated $10.2M.
  • Ghost Tree Capital's ten largest holdings make up 44% of its $244M portfolio in Q4 2015.
  • Ghost Tree Capital opened 19 new positions and closed 46 in Q4 2015.
  • Ghost Tree Capital's portfolio value rose 9.9% quarter-over-quarter to $244M.

Based on Ghost Tree Capital's 13F filing for Q4 2015, filed 16 Feb 2016.